The immunotherapy cemiplimab (Libtayo) looks set to have two further cancer indications in Europe: nonsmall cell lung cancer (NSCLC) and

Debulking large exophytic basal cell carcinomas prior to hedgehog inhibitor therapy might improve outcomes, according to Allison Vidimos, MD, a Mohs